A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin.

Published

Journal Article

OBJECTIVES: Very low birth weight (VLBW) infants are vulnerable to nosocomial infections and subsequent morbidity; including infections caused by Staphylococcus aureus: 85% of nosocomial S. aureus infections are caused by capsular polysaccharide (CPS) types 5 and 8. Altastaph is a polyclonal investigational human immunoglobulin G (IgG) with high levels of opsonizing S. aureus CPS types 5 and 8 IgG. METHODS: A Phase 2 clinical trial to assess the safety and kinetics of Altastaph in VLBW infants. Neonates in this multicenter study were randomized to receive two identical 20 ml/kg i.v. infusions of either 0.45% NaCl placebo or 1000 mg Altastaph/kg. Each infant was followed for 28 days after the second infusion or until discharge. Serum S. aureus CPS types 5 and 8 IgG levels were measured preinfusion and at various times after each infusion. RESULTS: Of 206 neonates, 158 received both infusions. Adverse events were similar in the two treatment groups. Six subjects (3% in each group) discontinued owing to an adverse event. Geometric mean anti-type 5 IgG levels were 402 and 642 mcg/ml 1 day following infusion of the first (day 0) and Second (day 14) doses, respectively, in neonates < or =1000 g and slightly higher in neonates 1001 to 1500 g. Trough levels before second infusion were 188 mcg/ml. Type 8 IgG levels were similar. Geometric mean IgG levels among placebo recipients were consistently <2 and <5 mcg/ml for types 5 and 8 in both weight groups. Three episodes of S. aureus bacteremia occurred in each arm. CONCLUSIONS: Infusion of Altastaph in VLBW neonates resulted in high levels of specific S. aureus types 5 and 8 CPS IgG. The administration of this anti-staphylococcal hyperimmune globulin was well tolerated in this population.

Full Text

Duke Authors

Cited Authors

  • Benjamin, DK; Schelonka, R; White, R; Holley, HP; Bifano, E; Cummings, J; Adcock, K; Kaufman, D; Puppala, B; Riedel, P; Hall, B; White, J; Cotton, CM; S. aureus prevention investigators,

Published Date

  • May 2006

Published In

Volume / Issue

  • 26 / 5

Start / End Page

  • 290 - 295

PubMed ID

  • 16598296

Pubmed Central ID

  • 16598296

Electronic International Standard Serial Number (EISSN)

  • 1476-5543

International Standard Serial Number (ISSN)

  • 0743-8346

Digital Object Identifier (DOI)

  • 10.1038/sj.jp.7211496

Language

  • eng